Q1 EPS Estimates for Trinity Biotech Decreased by Sidoti Csr

Trinity Biotech PLC (NASDAQ:TRIB) – Equities researchers at Sidoti Csr dropped their Q1 2025 earnings per share (EPS) estimates for shares of Trinity Biotech in a research report issued to clients and investors on Wednesday, June 11th. Sidoti Csr analyst J. Sidoti now expects that the company will earn ($0.57) per share for the quarter, down from their prior forecast of ($0.28). The consensus estimate for Trinity Biotech’s current full-year earnings is ($1.51) per share. Sidoti Csr also issued estimates for Trinity Biotech’s Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.77) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($1.09) EPS.

Separately, Wall Street Zen initiated coverage on Trinity Biotech in a research report on Saturday, May 17th. They set a “sell” rating for the company.

Trinity Biotech Price Performance

TRIB opened at $0.61 on Monday. The business has a 50 day simple moving average of $0.68 and a two-hundred day simple moving average of $0.76. The firm has a market capitalization of $10.97 million, a price-to-earnings ratio of -0.22 and a beta of 0.84. Trinity Biotech has a one year low of $0.48 and a one year high of $3.44.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.